Tag Archives: NASDAQ:LGND

The CEO of Ligand Pharma is Exercising Options

Today it was reported that the CEO of Ligand Pharma (LGND – Research Report), John L. Higgins, exercised options to buy 4,315 LGND shares at $70.01 a share, for a total transaction value of $302.1K. Following John L. Higgins’ last

H.C. Wainwright Reiterates Their Buy Rating on Ligand Pharma (LGND)

H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Ligand Pharma (LGND – Research Report) today and set a price target of $237.00. The company’s shares closed last Monday at $76.92. According to TipRanks.com, Pantginis is currently ranked with

H.C. Wainwright Keeps a Buy Rating on Ligand Pharma (LGND)

H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Ligand Pharma (LGND – Research Report) today and set a price target of $214.00. The company’s shares closed last Monday at $91.24, close to its 52-week low of $84.45. According

The EVP,Finance & Strategy and CFO of Ligand Pharma (NASDAQ: LGND) is Buying Shares

Yesterday, the EVP,Finance & Strategy and CFO of Ligand Pharma (LGND – Research Report), Matthew Korenberg, bought shares of LGND for $43.09K. In addition to Matthew Korenberg, 4 other LGND executives reported Buy trades in the last month. Following this

The CEO of Ligand Pharma (NASDAQ: LGND) is Buying Shares

Yesterday, the CEO of Ligand Pharma (LGND – Research Report), John L. Higgins, bought shares of LGND for $176.6K. This recent transaction increases John L. Higgins’ holding in the company by 1.28% to a total of $13.43 million. See today’s

The President & COO of Ligand Pharma is Exercising Options

Yesterday it was reported that the President & COO of Ligand Pharma (LGND – Research Report), Matthew W. Foehr, exercised options to buy 1,004 LGND shares at $21.92 a share, for a total transaction value of $22.01K. In addition to